By InvitationPhase 4

Reducing Hypotensive Anesthesia Use with TXA During Orthognathic Surgery

United States50 participantsStarted 2022-11-11

Plain-language summary

This prospective study will analyze the need for deliberate hypotensive anesthesia (DHA) during orthognathic surgery when tranexamic acid (TXA) is administered. DHA has been proven to be effective although it comes with multiple risks related to organ hypoperfusion including kidney injury, stroke, and cardiac ischemia. Therefore, it may be potentially safer for patients to avoid deliberate hypotensive anesthesia if TXA alone adequately controls blood loss and provides adequate surgical site visualization.

Who can participate

Age range12 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Bimaxillary orthognathic surgery completed at UAB Highlands Hospital Exclusion Criteria: * History of hypertension or previously diagnosed cardiac problems * Bleeding diathesis * TXA medically contraindicated

What they're measuring

Surgeon's Analysis of Surgical Field Visualization

Timeframe: 1 year

Mean Arterial Pressure

Timeframe: 1 year

Estimated Blood Loss

Timeframe: 1 year

Trial details

NCT IDNCT05474027

SponsorUniversity of Alabama at Birmingham

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-12

View on ClinicalTrials.gov More Hypotension During Surgery trials